DDInter1860 DDInter640
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Camazepam
Camazepam {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Halazepam
Halazepam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Halazepam
Halazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Triazolam {u} (Compound) resembles {v} (Compound) Halazepam
Halazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Camazepam (Compound) and Camazepam (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Halazepam (Compound) and Halazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Triazolam (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Encorafenib
Triazolam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Encorafenib
Triazolam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Encorafenib